The most serious side effects of tamoxifen include an increased risk of uterine cancer, blood clots, and stroke. These are rare but potentially life-threatening complications that distinguish tamoxifen from medications with only mild side effects. Most women taking tamoxifen will not experience these severe outcomes, but understanding them helps you recognize warning signs early and weigh the drug’s benefits against its risks.
Increased Risk of Uterine Cancer
Tamoxifen works by blocking estrogen in breast tissue, but it has the opposite effect in the uterus, where it actually stimulates the lining. This stimulation can lead to abnormal thickening, precancerous changes, and in some cases, endometrial cancer or uterine sarcoma. Most studies place the risk at two to three times higher than in women not taking the drug.
Age matters significantly. In women under 50, clinical trials found no statistically significant increase in endometrial cancer rates compared to placebo. In women 50 and older, the picture changes dramatically: the risk ratio jumps to about 4, meaning four times the expected rate. In absolute numbers from one large prevention trial, that translated to roughly 3 cases per 1,000 women per year on tamoxifen versus less than 1 case per 1,000 on placebo. The risk is real but still numerically small for any individual woman.
The key warning sign is abnormal vaginal bleeding, bloody discharge, staining, or spotting, particularly after menopause. Any of these symptoms while on tamoxifen warrants prompt investigation. Routine ultrasound screening of the uterine lining in women without symptoms has not been shown to be beneficial and is not recommended.
Blood Clots and Pulmonary Embolism
Tamoxifen increases the tendency of blood to clot, raising the risk of deep vein thrombosis (a clot in the leg) and pulmonary embolism (a clot that travels to the lungs). The estimated excess risk attributed to tamoxifen is roughly 0.3% to 1.9% per year. One large study of over 13,000 women with breast cancer found that tamoxifen use was associated with a hazard ratio between 1.9 and 5.5 for blood clots, meaning the risk roughly doubled to quintupled depending on other factors present.
The risk appears highest in the early period after starting treatment. A study of nearly 13,000 postmenopausal women found that the elevated clot risk was concentrated in the initial phase of tamoxifen use rather than building gradually over time. Warning signs include sudden leg swelling, pain or warmth in one leg, unexplained shortness of breath, or chest pain. These require immediate medical attention.
Stroke
Women treated with tamoxifen face an increased risk of ischemic stroke, the type caused by a blocked blood vessel in the brain. Research from the American Heart Association has linked tamoxifen treatment to an 82% increase in ischemic stroke risk. This is related to the same clot-promoting effect behind the blood clot risk. While the absolute numbers remain low, this is one of the most serious potential consequences and is worth discussing with your treatment team, especially if you already have cardiovascular risk factors like high blood pressure or a history of smoking.
Fatty Liver Disease
Tamoxifen can cause fat to accumulate in the liver at a surprisingly high rate. In one study of 67 breast cancer patients on tamoxifen, 43% developed fatty liver within the first two years of therapy. Of those, about half developed the condition in the first year alone. Most cases were mild, but some were moderate or severe. The encouraging finding: no new cases appeared after the two-year mark, and the condition reversed after tamoxifen was stopped.
Fatty liver from tamoxifen typically causes no symptoms, which is why it often goes undetected. In rare cases, it can progress to inflammation or scarring. If you’re on tamoxifen and have other risk factors for liver disease, such as obesity or heavy alcohol use, this side effect deserves extra attention.
Eye Damage
Tamoxifen can cause changes to the retina, the light-sensitive tissue at the back of the eye. Early studies found retinal changes in about 1% of patients, but more thorough screening has revealed the number may be considerably higher. A comprehensive review of the research concluded that retinal changes may occur in up to 12% of patients taking tamoxifen for at least two years. These changes can affect vision, sometimes permanently.
Symptoms of tamoxifen retinopathy include blurry vision, difficulty reading, or seeing colors differently. The condition develops gradually and may not be noticeable at first. Baseline eye exams before starting tamoxifen and periodic monitoring during treatment can catch changes before they progress.
Bone Loss in Premenopausal Women
Tamoxifen’s effect on bones depends entirely on your menopausal status. In postmenopausal women, it actually protects bone density, which is a benefit. In premenopausal women, the opposite happens. A meta-analysis found that premenopausal women on tamoxifen experienced significant bone loss, particularly in the lower spine, where bone mineral density dropped substantially over a median of three years. Hip bone loss also occurred, though the evidence was less consistent.
This matters because premenopausal women on tamoxifen may be starting from a point of otherwise healthy bone. Losing density during years of treatment could set the stage for osteoporosis later in life. Monitoring bone density during treatment and ensuring adequate calcium and vitamin D intake are practical steps to manage this risk.
Hot Flashes and Quality of Life
While not dangerous, hot flashes are the most common side effect and the one that most affects daily life. About 77% of women on tamoxifen experience them, with 11% reporting severe or very severe episodes. For many women, hot flashes are the reason they consider stopping treatment early, which creates a real tension between tolerability and the drug’s cancer-preventing benefits.
Hot flashes from tamoxifen can be more intense and frequent than natural menopausal hot flashes. They often disrupt sleep, which cascades into fatigue, irritability, and difficulty concentrating during the day. Because tamoxifen is used specifically in hormone-sensitive cancers, hormone replacement therapy is not an option for relief, which limits the available management strategies to non-hormonal approaches.
Mood and Cognitive Effects
Many women report mood changes, depression, or “brain fog” while taking tamoxifen, and these complaints are common in online patient communities. The clinical evidence, however, is more nuanced. A large randomized trial within the STAR study, which included thousands of postmenopausal women, found no significant differences in depression scores or cognitive performance between treatment groups over time. Scores on memory, attention, and mood measures actually improved over the course of the study in both groups, likely due to practice effects on the tests.
That said, the absence of a clear signal in clinical trials does not mean individual women don’t experience real cognitive or mood changes. About 20% of women in the STAR trial had a history of depression at baseline, and tamoxifen’s hormonal effects could plausibly worsen symptoms in susceptible individuals. If you notice persistent mood changes or difficulty thinking clearly after starting tamoxifen, it is worth raising with your care team rather than assuming it is unrelated.